About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

HCT Versus CT in Elderly AML | Clinical Trials | Clareo Health

TERMINATEDPhase 3

HCT Versus CT in Elderly AML

Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission

NCT00766779•European Society for Blood and Marrow Transplantation

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Acute Myeloid Leukemia

Interventions

hematopoietic cell transplantation

Non-Transplant treatment approach for consolidation

Locations

48

Australia

Locations (48)

The Alfred Hospital

Melbourne Victoria, Australia

Hanusch Krankenhaus der Wiener Gebietskrankenkasse

Vienna, Austria

Medizinische Universität Wien

Vienna, Austria

ZNA Stuivenberg - Ziekenhuis Netwerk Antwerpen

Antwerp, Belgium

UZ Gasthuisberg Leuven

Leuven, Belgium

Centre Hospitalier Sud Amiens

Amiens, France

Key Dates

Start Date

January 1, 2010

Primary Completion Date

December 1, 2020

Completion Date

December 1, 2020

Last Updated

October 14, 2021

Related Studies

RECRUITINGPhase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390

Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+3 more

Familial Investigations of Childhood Cancer Predisposition

NCT03050268

Acute LeukemiaAdenomatous Polyposis+44 more

RECRUITINGPhase 1

Imetelstat Combinations in Relapsed AML

NCT07320235

Relapsed Acute Myeloid Leukemia

Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy

NCT06439199

Acute Myeloid LeukemiaMyelodysplastic Syndromes+1 more

RECRUITINGPhase 2

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

NCT06782542

Acute Myeloid LeukemiaIDH1 Mutation

RECRUITINGPhase 1

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

NCT05886049

Acute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation

View all related studies

Sponsors

Lead Sponsor

European Society for Blood and Marrow Transplantation

Collaborators

Acute Leukemia French Association
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
European Organisation for Research and Treatment of Cancer - EORTC
French Innovative Leukemia Organisation
HOVON - Dutch Haemato-Oncology Association
East German Study Group of Hematology and Oncology (OSHO)
Swiss Cancer Institute

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 14, 2021Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions